CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention

被引：9
|
作者：
Williams, Alexis K. [1 ]
Klein, Melissa D. [2 ]
Martin, Jesse [1 ]
Weck, Karen E. [4 ]
Rossi, Joseph S. [2 ,3 ]
Stouffer, George A. [2 ,3 ]
Lee, Craig R. [1 ,3 ]
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA
[2] Univ N Carolina, Sch Med, Div Cardiol, Chapel Hill, NC USA
[3] Univ N Carolina, McAllister Heart Inst, Chapel Hill, NC USA
[4] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA
来源：
CIRCULATION-GENOMIC AND PRECISION MEDICINE | 2019年 / 12卷 / 02期
关键词：
cardiovascular diseases; clopidogrel; pharmacogenetics; precision medicine; IMPLEMENTATION;
D O I：
10.1161/CIRCGEN.119.002441
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：97 / 99
页数：3
相关论文
共 50 条
  • [1] Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Rajachandran, Manu
    Lange, Richard A.
    CURRENT CARDIOLOGY REPORTS, 2024, 26 (07) : 675 - 680
  • [2] Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Lee, Craig R.
    Sriramoju, Vindhya B.
    Cervantes, Alexandra
    Howell, Lucius A.
    Varunok, Nicholas
    Madan, Shivanshu
    Hamrick, Kasey
    Polasek, Melissa J.
    Lee, John Andrew
    Clarke, Megan
    Cicci, Jonathan D.
    Weck, Karen E.
    Stouffer, George A.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (04): : e002069
  • [3] Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Cavallari, Larisa H.
    Lee, Craig R.
    Beitelshees, Amber L.
    Cooper-DeHoff, Rhonda M.
    Duarte, Julio D.
    Voora, Deepak
    Kimmel, Stephen E.
    McDonough, Caitrin W.
    Gong, Yan
    Dave, Chintan V.
    Pratt, Victoria M.
    Alestock, Tameka D.
    Anderson, R. David
    Alsip, Jorge
    Ardati, Amer K.
    Brott, Brigitta C.
    Brown, Lawrence
    Chumnumwat, Supatat
    Clare-Salzler, Michael J.
    Coons, James C.
    Denny, Joshua C.
    Dillon, Chrisly
    Elsey, Amanda R.
    Hamadeh, Issam S.
    Harada, Shuko
    Hillegass, William B.
    Hines, Lindsay
    Horenstein, Richard B.
    Howell, Lucius A.
    Jeng, Linda J. B.
    Kelemen, Mark D.
    Lee, Yee Ming
    Magvanjav, Oyunbileg
    Montasser, May
    Nelson, David R.
    Nutescu, Edith A.
    Nwaba, Devon C.
    Pakyz, Ruth E.
    Palmer, Kathleen
    Peterson, Josh F.
    Pollin, Toni I.
    Quinn, Alison H.
    Robinson, Shawn W.
    Schub, Jamie
    Skaar, Todd C.
    Smith, D. Max
    Sriramoju, Vindhya B.
    Starostik, Petr
    Stys, Tomasz P.
    Stevenson, James M.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (02) : 181 - 191
  • [4] CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
    Beitelshees, Amber L.
    Thomas, Cameron D.
    Empey, Philip E.
    Stouffer, George A.
    Angiolillo, Dominick J.
    Franchi, Francesco
    Tuteja, Sony
    Limdi, Nita A.
    Lee, James C.
    Duarte, Julio D.
    Kreutz, Rolf P.
    Skaar, Todd C.
    Coons, James C.
    Giri, Jay
    McDonough, Caitrin W.
    Rowland, Rachel
    Stevenson, James M.
    Thai, Thuy
    Vesely, Mark R.
    Wellen, Jacob T.
    Johnson, Julie A.
    Winterstein, Almut G.
    Cavallari, Larisa H.
    Lee, Craig R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (04):
  • [5] Effect of Gender on Clinical Outcomes in Patients Receiving CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Gustafson, Chelsea
    Gower, Megan N.
    Williams, Alexis K.
    Pauley, Eric
    Weck, Karen E.
    Lee, Craig R.
    Stouffer, George A.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2020, 13 (05): : 554 - 556
  • [6] The effect of CYP2C19 genotype-guided antiplatelet therapy on outcomes of selective percutaneous coronary intervention patients: an observational study
    Tan, Kai
    Lian, Zhexun
    Shi, Yan
    Wang, Xiaxia
    Yu, Haichu
    Li, Mengwan
    Tian, Jianhui
    Ge, Yiping
    PERSONALIZED MEDICINE, 2019, 16 (04) : 301 - 312
  • [7] THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY
    Klein, Melissa
    Sriramoju, Vindhya B.
    Cervantes, Alexandra
    Varunok, Nicholas
    Madan, Shivanshu
    Weck, Karen
    Lee, Craig
    Stouffer, George
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1196 - 1196
  • [8] CYP2C19 GUIDED ANTIPLATELET THERAPY: A COST-EFFECTIVENESS ANALYSIS OF 30-DAY AND ONE-YEAR OUTCOMES FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
    Dong, O. M.
    Borse, M. S.
    Polasek, M. J.
    Farley, J. F.
    Stouffer, G. A.
    Lee, C. R.
    VALUE IN HEALTH, 2017, 20 (09) : A405 - A405
  • [9] Response by Lee and Stouffer to Letter Regarding Article, "Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention"
    Lee, Craig R.
    Stouffer, George A.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (07):
  • [10] Letter by Aw et al Regarding Article, "Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention"
    Aw, Jernice Wan Xin
    Tan, Doreen Su-Yin
    Goh, Liuh Ling
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (07):
12345